Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 51c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $230.56 -2.38%
Revenue Growth %: +6.2%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +6.2%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $3.67, $0.51 better than the analyst estimate of $3.16. Revenue for the quarter came in at $508.2 million versus the consensus estimate of $465.95 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2019 EPS of $14.30-$15.00, versus the consensus of $14.60. Jazz Pharmaceuticals sees FY2019 revenue of $2.05-2.13 billion, versus the consensus of $2.07 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Lennar Corp. (LEN) Misses Q2 EPS by 1c
- RH (RH) Tops Q1 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
